



What is Long COVID?

Dr. Nathan Erdmann

Recorded Webinar



PROGRAM OVERVIEW

Post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes known as "long-COVID," is a dynamic condition that sometimes occurs more than 4 weeks after initial COVID infection and can be characterized by a variety of symptoms. It is unclear why some individuals experience long-COVID. This program will explore the conditions, possible etiologies, and immunologic responses associated with long-COVID infection. There is no registration fee for this program.

Following registration, participants will have access to course instructions, updates, presentations, webinar link, program evaluation, CE certificates and credits, etc. **This program is approved for 1.0 ACPE Contact Hours, .1 CEUs.** Once credit is awarded, transcripts will be available online within 24 hours on the learner's CPE Monitor profile at http://nabp.pharmacy/. **This program is also approved by ABN.**

The Office of Alumni and Professional Affairs strongly encourages each participant to check their profile online within 60 days of attendance to ensure credit has been awarded properly. ACPE will not accept CE submissions after 60 days from the live seminar date.

This project was funded in part through a grant from the National Heart, Lung, and Blood Institute, Sub-OTA No. 6922-03-COVID-S002 - Alabama Community Engagement Alliance against COVID-19 Disparities (Alabama CEAL) project, under subcontracts with Research Triangle Institute and Westat, Inc.

TARGET AUDIENCE

This knowledge-based program is intended for Pharmacists (ACPE) and Nurses (ABN).

LEARNING OBJECTIVES

- •Define Long-COVID
- •Identify the different symptoms associated with long-COVID
- Describe the immunological effects associated with long-COVID

ACTIVITY COMPLETION REQUIREMENTS

To complete the steps for CE credit, each attendee will be required to access and review program materials located within the online course, watch the recorded webinar, take the quiz, complete the program evaluation within the online course, and claim credit within the course. Please contact hcopce@auburn.edu if you have any questions or needs related to this online CE program.

FACULTY DISCLOSURES

Programming in with AUHCOP is in any way involved, whether as sole provider or joint-providership, shall exhibit fair content balance, providing the audience with information of multiple perspectives from which to form a professional opinion. In addition, the fair balance will assure than information provided does not discuss since commercial product. Brand names of all products included in the content may be mentioned for identification purposes only. Presenters in any continuing education offering will acknowledge and disclose any affiliation with the provider and such information will be made available to the audience. Faculty disclosures will also be included on an introductory slide during the presentation. Dr. Nathan Erdmann has the following disclosures, but his involvement did not affect the material identified or presented for this program and that the material presented in this program was developed from an unbiased perspective

Disclaimer:

- \bullet Investigator on the NIAID Adaptive COVID-19 Treatment Trial (ACTT)
- (NCT04280705, PI: J. Beigel)
- NIH sponsored COVID-19 Prevention Network (CoVPN)
- NIH RECOVER Study
- Financial Interests:
- Intellectual Property (IP), "Human neutralizing antibodies against SARS-CoV-2 / COVID-19" licensed to the Plantform Corp
- Perspectum Scientific Advisory Board

ACCREDITATION INFORMATION

The Auburn University Harrison College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is **0001-9999-24-014-H01-P** and is intended for pharmacists. The initial release date for this program is March 7, 2024, and the intended expiration date is March 7, 2027.

ABN - Auburn University Harrison College of Pharmacy is a Board approved provider of continuing nursing education in Alabama by the Alabama Board of Nursing. Provider Number: ABNP1515

PROGRAM FACULTY

Nathan Erdmann, MD, Ph.D., completed his MD/Ph.D. with a focus on HIV pathogenesis at the University of Nebraska Medical Center. During Infectious Diseases fellowship, he studied the effects of T cell responses on viral adaptation with a goal of developing new strategies for HIV vaccination. In response to the pandemic, he led numerous clinical and research efforts, leading trials assessing antiviral and immunomodulatory interventions and coordinated a multidisciplinary effort to establish a robust COVID-19 cohort. The samples and data for this research cohort led to multiple publications and provided the basis for UAB's selection as a hub for the NIH Long COVID effort RECOVER. Nathan is the PI for UAB and is MPI on multiple grants exploring the mechanisms of Long COVID. He is Medical Director of the UAB 1917 HIV Clinic where he supervises patient care and leads the educational curriculum for fellows and providers.

POST-GRADUATE EDUCATION ADVISORY COMMITTEE

Spencer Durham, Pharm.D., BCPS, BCIDP

Associate Clinical Professor, Director of Alumni & Professional Affairs

Jack DeRuiter, Ph.D.

Alumni Professor, Drug Discovery and Development

Natalie Hohmann, Pharm.D., Ph.D.

Alumni Professor, Drug Discovery and Development

Amal Kaddoumi, Ph.D.

Professor, Drug Discovery and Development

Erika Kleppinger, Pharm.D., BCPS

Associate Clinical Professor, Pharmacy Practice

Kristen Korankyi, Pharm.D.

Assistant Clinical Professor, Pharmacy Practice

Amit Mitra, Ph.D.

Assistant Professor, Drug Discovery and Development

Sylvia Rogers, Ph.D.

Senior Instructional Designer, Faculty Affairs and Strategic Initiatives

Brianna Foster

Program Administrator, Alumni and Professional Affairs

Tanja Redd, MBA, Ph.D.

Program Coordinator, Alumni and Professional Affairs

Members of the Post-Graduate Education Advisory Committee have completed a conflict-of-interest disclosure form and have no actual or potential conflicts of interest in relation to this program.